The challenge of targets and drug discovery using large-scale screening approaches in onco-hematology

Lina Benajiba; Jean-Jacques Kiladjian

doi:10.1016/j.therap.2021.11.007

The challenge of targets and drug discovery using large-scale screening approaches in onco-hematology

Therapie. 2022 Mar-Apr;77(2):151-155. doi: 10.1016/j.therap.2021.11.007. Epub 2021 Nov 25.

Authors

Lina Benajiba¹, Jean-Jacques Kiladjian²

Affiliations

¹ Inserm CIC1427, Clinical Investigations Center, hôpital Saint-Louis, université de Paris, AP-HP, 75010 Paris, France; Inserm UMR 944, Saint-Louis Research Institute, 75010 Paris, France.
² Inserm CIC1427, Clinical Investigations Center, hôpital Saint-Louis, université de Paris, AP-HP, 75010 Paris, France; Inserm UMR 1131, Saint-Louis Research Institute, 75010 Paris, France. Electronic address: jean-jacques.kiladjian@aphp.fr.

PMID: 34895756
DOI: 10.1016/j.therap.2021.11.007

Abstract

Target identification and drug discovery roads have been widely improved over the past decades in onco-hematology. In this review, we summarize recent improvements in the use of physio-pathologically relevant models and innovative screening approaches to accelerate efficient drug development. Using acute myeloid leukemia as an example, we also discuss the main encountered pitfalls and propose alternative roads to improve the drug discovery journey in onco-hematology.

Keywords: Drug discovery; Large-scale screening; Onco-hematology; Target identification.

Publication types

Review

MeSH terms

Drug Discovery
Hematology*
Humans